784 件 ・ 関連度順
概要と使いどころ
Guide for creating effective skills. This skill should be used when users want to create a new skill (or update an existing skill) that extends Codex's capabilities with specialized knowledge, workflows, or tool integrations.
日本語の概要は準備中です。原文の説明を表示しています。
Guidance for using asc cli in this repo (flags, output formats, pagination, auth, and discovery). Use when asked to run or design asc commands or interact with App Store Connect via the CLI.
日本語の概要は準備中です。原文の説明を表示しています。
Run an offline ASO audit on canonical App Store metadata under `./metadata` and surface keyword gaps using Astro MCP. Use after pulling metadata with `asc metadata pull`.
日本語の概要は準備中です。原文の説明を表示しています。
Build, run, and debug iOS apps on Simulator with XcodeBuildMCP. Use when launching an app, inspecting simulator UI or logs, or diagnosing runtime behavior.
日本語の概要は準備中です。原文の説明を表示しています。
Triage TestFlight crashes, beta feedback, and performance diagnostics using asc. Use when the user asks about TF crashes, TestFlight crash reports, beta tester feedback, app hangs, disk writes, launch diagnostics, or wants a crash summary for a build or app.
日本語の概要は準備中です。原文の説明を表示しています。
Archive, export, and notarize macOS apps using xcodebuild and asc. Use when you need to prepare a macOS app for distribution outside the App Store with Developer ID signing and Apple notarization.
日本語の概要は準備中です。原文の説明を表示しています。
Use when the user asks to modify an existing rough cut — shorten, lengthen, remove a clip, reorder, change BGM, adjust pacing. Works by generating a review_patch and re-compiling.
日本語の概要は準備中です。原文の説明を表示しています。
Implements missing-data sensitivity analyses for confirmatory clinical trials including MMRM under MAR (with Kenward-Roger correction), reference-based multiple imputation (J2R, CR, CIR, LMCF per Carpenter-Roger 2013), Permutt delta-adjustment / tipping-point analysis, pattern-mixture identifying restrictions (CCMV, NCMV, ACMV), and the Cro vs Bartlett variance debate. Use when handling missing primary or secondary endpoint data in regulatory submissions following NRC 2010 and ICH E9(R1).
日本語の概要は準備中です。原文の説明を表示しています。
Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.
日本語の概要は準備中です。原文の説明を表示しています。
Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.
日本語の概要は準備中です。原文の説明を表示しています。
Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Decision-grade statistical analysis for metabolomics intensity tables. Covers transformation and scaling (Pareto vs unit-variance as a hidden hypothesis), unsupervised structure (PCA/HCA for QC), permutation-validated PLS-DA/OPLS-DA (R2 vs Q2, double CV, VIP as heuristic), univariate testing (Welch/Mann-Whitney/ANOVA/LMM with covariate adjustment), and dependence-aware multiple testing. Use when testing which metabolites differ, building or validating a discriminant model, choosing a scaling, or correcting many correlated tests. For sample-wise normalization/drift correction see metabolomics/normalization-qc; for ML classifiers and selection-inside-CV leakage see machine-learning/biomarker-discovery and machine-learning/model-validation; for pathway interpretation see metabolomics/pathway-mapping; for design/power/multiplicity regime see experimental-design/multiple-testing.
日本語の概要は準備中です。原文の説明を表示しています。
Runs a single ScenarioRunner Python scenario (or a whole group) against a running CARLA server — FollowLeadingVehicle, ControlLoss, DynamicObjectCrossing, SignalizedJunctionLeftTurn and the rest of srunner/examples — in sync or async mode, with result output, recording and manual/agent control of the ego. Lists what is runnable on the checked-out branch and on the loaded map. Use when the user asks to "run a scenario", "test FollowLeadingVehicle", "list scenarios", "run a CARLA traffic scenario", or reports a scenario that is "not supported".
日本語の概要は準備中です。原文の説明を表示しています。
ABP Framework cross-cutting patterns including authorization, background jobs, distributed events, multi-tenancy, and module configuration. Use when: (1) defining permissions, (2) creating background jobs, (3) publishing/handling distributed events, (4) configuring modules.
日本語の概要は準備中です。原文の説明を表示しています。
Explore possible next roles from a user's actual tasks, interests, and constraints, including adjacent roles and changes within their current workplace. Build evidence-linked career hypotheses, identify unknown duties and requirements, and propose small ways to test them. Use when someone does not know what work to pursue or asks what they could do beyond their current job; do not diagnose aptitude, rank careers, or predict salary or hiring success.
日本語の概要は準備中です。原文の説明を表示しています。
Design what an employer will have a candidate do during an Otameshi Tenshoku trial: turn a business problem into a bounded paid assignment or an unpaid learning visit, with scope, completion criteria, candidate hours, company staff hours, duration, compensation and change conditions, and check the planned cost against the budget. Use when a hiring manager, recruiter or small-business owner wants to decide what work to offer, how much time it takes, what it costs, or how to adjust a plan when materials are late or the scope grows; do not use to write the public listing (trial-listing-draft), to reply to applicants (applicant-reply), to state market rates, legal, tax or service conditions from memory, or to post, contact or contract on the user's behalf.
日本語の概要は準備中です。原文の説明を表示しています。
Infer or annotate TCR antigen specificity by unsupervised clustering (TCRdist/tcrdist3, GLIPH2, clusTCR, GIANA) and database lookup (VDJdb, IEDB, McPAS-TCR), and rank candidates with supervised predictors (ERGO-II, NetTCR-2.x, pMTnet) under explicit caveats. Encodes the central truth that general TCR-epitope prediction for UNSEEN epitopes essentially does not work (collapses to near-random; IMMREP22, Grazioli 2022) because labeled data is dominated by a few immunodominant epitopes and there is no true negative set — so clustering for discovery is the honest task and de-novo binding needs wet-lab validation. Use when annotating TCR specificity or grouping a repertoire. Epitope/MHC context lives in mhc-binding-prediction.
日本語の概要は準備中です。原文の説明を表示しています。
Performs differential expression on bulk RNA-seq count data with DESeq2's negative-binomial GLM, Wald and LRT testing, apeglm/ashr/normal LFC shrinkage, independent filtering, Cook's outlier handling, VST/rlog transforms, and design formulas including paired, batch, and interaction terms. Use when running bulk DE, choosing DESeq2 over edgeR or limma-voom, building a paired or interaction design, applying LFC shrinkage for ranking or GSEA, choosing Wald vs LRT, troubleshooting padj=NA, picking VST vs rlog, importing salmon/kallisto via tximport, or analyzing prokaryotic RNA-seq.
日本語の概要は準備中です。原文の説明を表示しています。
Add p-value brackets, significance asterisks, and effect-size annotations to distribution plots using ggpubr, ggsignif, and statannotations with correct test selection (parametric vs non-parametric vs paired), multiple-testing adjustment, and rendering of negative results. Use when a boxplot/violin/raincloud needs in-figure statistical comparisons between groups.
日本語の概要は準備中です。原文の説明を表示しています。
Build volcano and MA plots from differential-expression / association results with LFC shrinkage, FDR-adjusted thresholds, sensible label placement, and axis-truncation conventions. Covers EnhancedVolcano, ggplot2, matplotlib, and the apeglm/ashr/normal shrinkage decision. Use when visualizing differential-expression results (RNA-seq, ChIP-seq, ATAC-seq, proteomics) or any per-feature effect-size + p-value table.
日本語の概要は準備中です。原文の説明を表示しています。
Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.
日本語の概要は準備中です。原文の説明を表示しています。
Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.
日本語の概要は準備中です。原文の説明を表示しています。
Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Detect and adjust for horizontal pleiotropy in two-sample Mendelian randomization by distinguishing uncorrelated (UHP) from correlated (CHP) pleiotropy and choosing among Egger, MR-PRESSO, MR-RAPS, CAUSE, LHC-MR, LCV, MR-Clust, MR-Mix, and contamination-mixture methods. Use when validating an MR causal claim, running the STROBE-MR sensitivity battery, suspecting a shared heritable confounder, working under weak-instrument or polygenic-exposure regimes, or reconciling discordant estimates across robust methods.
日本語の概要は準備中です。原文の説明を表示しています。